Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Change in Account Payables: 2020-2025

Historic Change in Account Payables for Legend Biotech (LEGN) over the last 5 years, with Sep 2025 value amounting to $24.3 million.

  • Legend Biotech's Change in Account Payables rose 289.32% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.3 million, marking a year-over-year increase of 350.74%. This contributed to the annual value of $14.1 million for FY2024, which is 128.01% up from last year.
  • Legend Biotech's Change in Account Payables amounted to $24.3 million in Q3 2025, which was up 46.85% from $16.5 million recorded in Q2 2025.
  • Legend Biotech's Change in Account Payables' 5-year high stood at $41.9 million during Q4 2022, with a 5-year trough of -$34.5 million in Q4 2023.
  • In the last 3 years, Legend Biotech's Change in Account Payables had a median value of -$2.0 million in 2024 and averaged $2.2 million.
  • In the last 5 years, Legend Biotech's Change in Account Payables skyrocketed by 4,178.72% in 2022 and then tumbled by 430.02% in 2023.
  • Legend Biotech's Change in Account Payables (Quarterly) stood at -$4.5 million in 2021, then soared by 1,021.80% to $41.9 million in 2022, then tumbled by 182.21% to -$34.5 million in 2023, then soared by 117.51% to $6.0 million in 2024, then spiked by 289.32% to $24.3 million in 2025.
  • Its Change in Account Payables stands at $24.3 million for Q3 2025, versus $16.5 million for Q2 2025 and $19.5 million for Q1 2025.